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Abstract
Duchenne muscular dystrophy cardiomyopathy (DMD-DCM) is characterized  
by progressive ventricular dilation and dysfunction that can begin at any age and 
worsens over time. Thanks to the lengthening of life expectancy due to better 
management of respiratory involvement, end-stage heart failure (HF) is becom-
ing the main cause of death for DMD patients. Therefore, from the time of DMD 
diagnosis, every effort should be focused to early detect the onset and the worsening 
of the DMD-DCM, with the aim of starting and modulating the therapy to slow 
the progression of cardiac dysfunction. In cardiac evaluation, biomarkers, elec-
trocardiograms, and echocardiograms must be considered, but cardiac magnetic 
resonance (CMR) is now acquiring a leading role due to its sensitivity in the earlier 
identification of cardiac involvement. The management of DMD-DCM at end stage 
is a difficult challenge that requires a multidisciplinary team composed of clinical 
cardiologists, electrophysiologists, cardiac surgeons, neuromuscular specialists, 
and psychologists. Because of the lack of specific drugs for DMD, we will review the 
actual cardiovascular armamentarium including drugs used for HF.
Keywords: duchenne muscular dystrophy, DMD, dilated cardiomyopathy, 
neuromuscular disease, dystrophin, heart failure
1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked degenerative neuromus-
cular disease that affects the skeletal muscles and the heart and over time leads to 
loss of walking, severe respiratory complications and progressive cardiac dilation 
and dysfunction.
It is caused by a mutation of the DMD gene, the largest gene in the human 
genome, mapped on the X-chromosome that codes for dystrophin, an essential 
protein for the stability of the myocyte membranes. The type of mutation and the 
degree of reduced expression of this structural protein influences the degree of 
muscle and cardiac impairment and especially the speed of myopathy progres-
sion. The milder forms are generally identified with the term Becker’s muscular 
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dystrophy (BMD) while the most severe and rapidly evolving forms, due to a severe 
reduction or total absence of dystrophin, are properly defined as DMD. Due to 
the X-linked recessive inheritance, the condition of female carriers must also be 
considered; they have a second normally functioning allele of dystrophin gene, 
thus they are generally characterized by a completely normal muscular and cardiac 
phenotype but may also present a mild/variable expression of the disease [1].
The incidence of DMD is approximately 1 in 5000 live male births, with 2/3 of 
the cases due to the transmission of the X-chromosome containing the mutated 
gene from a carrier female to male offspring and the remaining 1/3 of cases conse-
quent to de novo mutations.
Generally the first manifestation of the DMD is muscle weakness that begins 
around the age of four and worsens quickly, leading to the loss of independent 
walking by the age of ten and to respiratory dysfunction around the second decade 
of life. The cardiac involvement begins around 6–10 years of age [2, 3] while 
cardiovascular symptoms are rare before the age of twenty and often appear when 
the degree of cardiac dysfunction is severe [4].
In last decades, the life expectancy of patients with DMD has grown consider-
ably as a result of advances in the prevention and management of respiratory 
complications. As a result, there has been a significant increase in manifestations 
of advanced cardiomyopathy that is becoming the main cause of morbidity and 
mortality for these patients. This has led to a growing interest in the prevention and 
management of DMD-DCM [5–7].
While some aspects of DMD-DCM assessment and therapy are well defined 
by current guidelines [8], such as the need of routine cardiac evaluation and the 
indication to start prophylactic cardio-protective therapy from the age of ten in 
all patients, many other aspects remain under investigation, especially at end 
stage phase.
2. Genetic basis and pathophysiology of DMD-DCM
The DMD gene, encoded on the X chromosome, is the longest gene of our 
genome; it contains long introns with many “hotspots” susceptible to a high rate 
of mutations which can lead to the deletion (60–65% of all DMD mutations) or 
duplication (10%) of one or many exons. Shorter mutations such as point mutations 
are responsible for the remaining 25% of DMD cases. One third of DMD cases are 
due to de novo mutations while two third are inherited. The mutations resulting 
in the production of a truncated protein or of a dystrophin lacking in structural 
domains necessary for interaction with other proteins, are responsible for the most 
severe forms of the disease [9].
Dystrophin is a long intracellular protein of 3685 aminoacids and a molecular 
weight of 427 kDa. It is composed by four domains: an amino-terminal domain that 
interacts with actin of the myocyte cytoskeleton, a central rod-like domain that con-
tains sites of interaction with anionic lipids and with neural NOS, a second actin-
binding motif and four short proline-rich spacers responsible of the elasticity of 
the protein, a cysteine-rich domain that provides the protein–protein interaction and 
stabilizes dystroglycan binding, and a C-terminal domain, that interacts with several 
cytoplasmic, integral membrane and extracellular glycoproteins to create a protein 
complex called DAPC (dystrophin-associated protein complex) (Figure 1). The 
DAPC, in healthy myocytes, anchors the cytoskeleton and the plasma membrane to 
the extracellular matrix, ensuring stability and resistance to cells during contrac-
tions [9]. The lack of dystrophin, or the presence of an abnormal dystrophin, causes 
the loss of stability of this complex connection system with consequent greater 
3
Cardiomyopathy in Duchenne Muscular Distrophy: Clinical Insights and Therapeutic Implications
DOI: http://dx.doi.org/10.5772/intechopen.97022
fragility of the cell membrane of myocytes, dysregulation of cellular signaling and 
high susceptibility to damage and cell death. Cellular stress and cardiomyocyte 
death cause the release of cytokines, chemokines and cellular debris that attract 
neutrophils, macrophages and, later in time, fibroblasts. This process leads to the 
replacement of the heart muscle with fibrous tissue; it generally starts from the 
region behind the posterior mitral valve apparatus and proceeds toward the ven-
tricular apex and around the heart, and from the epicardium to the endocardium, 
to lead, ultimately, to the dilation and the dysfunction of the ventricles [10]. In this 
scenario, inflammation, dysregulation of the intracellular calcium (Ca2+) signaling, 
alteration of synthesis of nitric oxide, inadequate anti-oxidant response, mitochon-
drial malfunction and deficiency of membrane repair systems are all mechanisms 
involved in the molecular pathogenesis of DMD-DCM and they can be addressed 
for the development of new disease-modifier therapies [11].
Fibrosis, abnormal Ca2+ homeostasis and elevated reactive oxygen species are 
also predisposing factor to the onset of ventricular arrhythmias in DMD-DCM. 
Recently, a predisposition to pacing induced ventricular arrhythmias was dem-
onstrated in an animal model of DMD. In this model, the aberrant Ca2+ release 
through RyR2, which leads to delayed after depolarizations (DADs) and triggered 
ventricular arrhythmias, was related to the oxidated Ca2+/calmodulin-dependent 
protein kinase II, Ox-CaMKII. Genetic inhibition of Ox-CaMKII normalized intra-
cellular Ca2+ and prevented ventricular arrhythmias in this model [12]. Another 
interesting study suggested that arrhythmias could also result from an alteration of 
the components of the cardiac gap junction; in particular it has been proposed that 
the dislocation and anomalous S-nitrosylation of connexin 43 (Cx43) lead to the 
early depolarization of the cytoplasmic membrane and the consequent generation 
of action potentials. Then, these channels can be therapeutic targets to prevent fatal 
arrhythmias in patients with DMD [13].
3. Clinical course
The diagnosis of DMD may occur around 4 yo for difficulty in gait, calf 
hypertrophy, delayed speech, inability to jump or stand without using the arms 
for assistance (Gower maneuver), toe walking and difficulty in climbing stairs. 
Figure 1. 
The dystrophin- associated protein complex (DAPC). Dystrophin and DAPC plays an essential structural 
role in linking the actin of cytoskeleton to the extracellular matrix. The subunits of the DAPC, such as 
the sarcoglycans, have a vital role in the maintenance of muscle integrity. Dystrophin, a flexible rod-like 
cytoplasmic protein, directly interacts with the actin polymers of the cytoskeleton and with a complex of 
transmembrane glico-proteins composed by sarcoglycans, beta- and alpha-dystroglycan that creates a connection 
with the extracellular matrix by its linking with laminin-2.
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Over the time the progressive muscle waste leads to loss of ambulatory capacity 
and to decline of respiratory and cardiac functions [14].
Literature reports the beginning of ongoing cardiac disease processes as around 
6–10 years of age. Echocardiographic abnormalities and clinical DCM can occur at 
any age but often appear around 14–15 yo and are common over 18 years of age [15]. 
Symptoms are mild or completely absent up to the most advanced stages of cardio-
myopathy, and this is mainly due to the significant reduction in oxygen consump-
tion and in energy expenditure consequent to muscle weakness. It is remarkable 
that often the severity of cardiomyopathy does not correlate with the degree of 
skeletal muscle weakness, thus regular cardiac evaluation is very important also 
in patients with mild motility impairment and it is required before any invasive 
diagnostic procedure or surgery.
In the last decade, the increase in life expectancy, deriving from the better man-
agement of the respiratory involvement and the improved supportive cares, have 
resulted in a sharp increase in the number of patients with severe cardiomyopathy, 
and to date, end-stage HF has becoming one of the leading causes of morbidity and 
mortality in DMD [6].
Data from a multicentre Pediatric Cardiomyopathy Registry (PCMR) show a 
high prevalence of DCM also in milder forms of dystrophinopathies as in BMD (up 
to 90% of cases). Interestingly, in these patients, detection of cardiomyopathy often 
occurs at a more advanced stage and the progression of the LV dysfunction and 
dilation may be more rapid than in patients with DMD. Despite this, mortality rate 
for DMD patients with DCM is significantly worse than that of BMD patients, who 
can undergo heart transplant [16].
4. Noninvasive assessing of DMD-DCM
From the time of DMD diagnosis, every effort should be focused to detect early 
the onset and the progression of DCM. Early recognition and periodic re-evaluation 
are essential to guide therapy and to identify patients at increased risk of progres-
sion of cardiomyopathy and major cardiac events. Clinical evaluation remains 
challenging because most of these patients have often low blood pressure values and 
cool extremities because of reduced skeletal muscular mass even in the presence of 
hemodynamic compensation. Therefore, multiparametric evaluation is crucial to 
correctly recognize the progression of cardiac impairment [8].
4.1 Cardiovascular biomarkers
Serum biomarkers are often very useful for the diagnosis and monitoring 
heart disease. In particular, serum levels of cardiac troponin I/T are known to be 
associated to the extension of myocardial damage, but there are conflicting results 
about their diagnostic and prognostic implications in the DMD-DCM. Actually, 
only troponin I showed to be reliable in patients with neuromuscular disorder [17]. 
Troponin I levels seem to be significantly elevated in patients with initial myocar-
dial fibrosis expressed by mild late gadolinium enhancement (LGE) at the cardiac 
magnetic resonance (CMR) compared to those without LGE. Interestingly, this 
positive association between troponin levels and myocardial fibrosis is lost when 
LGE degree becomes moderate-to-severe, probably because at advanced stage of 
cardiomyopathy most of myocardium is already substituted by fibro-fatty tissue, 
therefore the release of myocardio-necrosis enzymes is reduced [18].
Natriuretic peptides are well established markers of HF and congestion in DCM. 
In DMD, pulmonary hypertension caused by impairment of the respiratory muscles 
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and restrictive physiopathology are considered to be involved in the mechanism of 
increased values of plasma natriuretic peptide. In addition to the more commonly 
used brain natriuretic peptide (BNP), a significant elevation in plasma alpha-atrial 
natriuretic peptide (alphaANP) levels is found as a sign of a poor prognosis and may 
be a useful index for the management of patients with DMD-DCM [19].
In the management of HF is very important to assess renal function. In DMD 
serum creatinine values  are generally very low as a consequence of their reduced 
muscle mass and therefore creatinine cannot be considered a good marker of renal 
function. In these patients, serum values of cystatin C, a protein produced by all 
cells, not only by muscle cells, are a good parameter for assessing renal function, 
because they better correlate with glomerular filtration rate (GFR) and cardiac 
dysfunction. Furthermore, it is reported a significant correlation between Cystatin 
C and cardiac dysfunction, providing for the first time a novel marker to identify 
cardio-renal syndrome in patients with DMD [20].
4.2 Electrocardiography and cardiac imaging
Electrocardiogram and transthoracic echocardiogram are the two fundamental 
exams advised to establish baseline cardiac involvement and they are recommended 
annually in all patients since the diagnosis of DMD. After the age of ten, cardiac 
assessment should have been at least yearly because of the increased risk of DCM. 
Even in the absence of abnormalities on the echocardiogram, a CMR should be 
performed in all children without contraindications from 7 years of age, when it is 
possible to perform this examination without the need for anesthesia, with the aim 
to detect early any regional dysfunction or myocardial fibrosis. When some abnor-
malities are found, controls should be more frequent [8].
Electrocardiographic (EKG) changes are very common (up to 90%). Initially, 
myocardial dystrophy may manifest itself as mild nonspecific EKG changes such 
as increased R-wave voltage in right or left precordial leads, QRS fragmenta-
tion, or slight alterations in ventricular repolarization. When cardiac disease is 
overt, R-wave voltage decreases and abnormal Q waves may appear generally in 
infero-lateral leads. ECG often shows also one of the following features: right axis 
deviation, conduction defects or short PR intervals, polyphasic R waves in V1, right 
bundle branch block, flat and inverted T waves, and prolonged heart rate-corrected 
QT interval. Sinus tachycardia is very common in DMD and, together with the 
reduction of circadian index and the scarce heart rate variability, it is a sign of the 
autonomic dysfunction that often affect these patients. 24-hours ECG monitoring is 
essential to detect autonomic dysfunction and it is recommended in case of suspect 
of arrhythmias and for routine monitoring of advanced stage of DMD-DCM, in 
which the presence of atrial fibrillation, atrial or ventricular arrhythmias may affect 
prognosis and change the management [21].
Echocardiography allows to identify the LV dilation, defined in children by a LV 
end-diastolic diameter that exceeds the mean value expected for age and sex by two 
standard deviations, and LV systolic dysfunction, defined by a LV ejection fraction 
(LVEF) <55% or a fractional shortening (FS) <28% [22]. Despite the advances in 2D 
and 3D techniques, FS is still considered the best surrogate of LV systolic function, 
among the echocardiographic possibilities, for its high reproducibility and its strong 
correlation with CMR LVEF [23]. Furthermore, routinely recognition of diastolic 
dysfunction is important because it is very frequent in all stages of DCM and can 
precede contractile impairment.
For earlier detection of LV impairment, speckle tracking echocardiography is also 
very useful, as it is a technique able to evaluate subclinical LV dysfunction before 
development of overt LVEF reduction. Global longitudinal strain (GLS), obtained by 
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2D speckle tracking echocardiography is abnormal in nearly 50% of DMD patients 
with a normal LVEF, and a decrease of 0,34% per year of GLS in DMD patients 
according to age has been recently reported [24]. The lowest values of strain is often 
observed in the inferolateral and anterolateral mid-basal segments. However, speckle 
tracking analysis is often limited in DMD because echocardiographic image quality is 
poor in these patients and declines by 2,5% for each 1 year increase in age because of 
chest deformities, lung hyperinflation, and limited mobility [25].
CMR is becoming the gold standard exam in the evaluation of DMD-DCM, 
especially because it allows a non-invasive myocardial tissue characterization by 
LGE and T1 mapping techniques, using non –ionizing radiations. It also offers the 
possibility to better analyze the size and global and regional kinetics of the left and 
right ventricles, not being limited by body habitus and providing a more accurate and 
reproducible three-dimensional views if compared to echocardiography. LGE identi-
fies fibrosis, it may have a subepicardial or transmural distribution, it is often initially 
localized in the inferolateral wall, and its extension allows to stratify the severity 
of cardiac involvement. LGE is an independent predictor of adverse cardiac events 
in DMD patients, also in those with a preserved LVEF [26]. T1 mapping technique 
pre- and post-contrast is able to identify diffuse fibrosis even earlier than LGE but T1 
mapping value varies a lot depending on the sequence used, and it cannot discrimi-
nate diffuse myocardial fibrosis from inflammation or fat infiltration [27]. Finally, 
CMR can also provide myocardial strain analysis, using feature-tracking technique.
CMR can be useful also to evaluate more precisely the severity of myocardial 
dysfunction and fibrosis in further stages, to assess the efficacy of anti-remodeling 
therapy, to screen asymptomatic DMD female carriers. However, the high costs, 
patient’s claustrophobia and the technical difficulties to obtain the exam in patients 
with home ventilator may limit its use in this group of patients.
5. Management of DMD-DCM from prevention to end-stage HF
In the clinical course of DMD-DCM three stages of DCM can be distinguished: a 
pre-clinical stage, a clinical stage and an end-stage DCM (Figure 2).
The pre-clinical stage is characterized by normal dimension and function of the 
heart. It usually limited to the early teenager years of life. In this phase, although 
the LV contractile function is preserved (LVEF>55%), the process of myocyte 
damage and fibrotic myocardial replacement has generally already begun and it can 
manifest itself with nonspecific EKG changes, subtle local wall motion abnormali-
ties, diastolic dysfunction consequent to cardiomyocyte hypertrophy, reduction in 
ventricular strain values and LGE at CMR.
At this stage of the DMD-DCM, the aim will be to delay the onset of ventricular 
contractile dysfunction. Current recommendation advices to start angiotensin con-
verting enzyme inhibitor (ACE- I) as preventive strategy. Perindopril 2–4 mg/die, 
[28] or an angiotensin receptor blocker (ARB) can be prescribed in all DMD patients 
from the age of ten. The indication to start therapy earlier, in patients with initial 
signs of cardiac involvement (such as the presence of mild LGE) but with preserved 
contractile function is still under debate and investigation [8].
At this early phase of DCM, when LV is mildly dilated, the use of mineralo-
corticoid receptor antagonist (MRA), such as eplerenone or spironolactone, may 
slow the rate of decline of LV function. Further studies are needed to determine 
the effect of combined cardioprotective therapy on event-free survival in these 
patients [29, 30].
The clinical stage includes a wide range of patients, with various degree of LV 
dilation and dysfunction, without any symptoms or with initial signs or symptoms 
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of HF. This phase can start at any age but frequently it begins after the age of ten. 
Few studies have focused on treating DMD patients with mild to moderate LV 
systolic dysfunction (LVEF>30% <50%), and the current consensus statement 
supports the use of traditional treatment for HF to treat the progression of DCM. 
All patients with at least mild ventricular dysfunction should be treated with an 
ACE-I or an ARB. In particular lisinopril (ACE-I) and losartan (ARB) have shown 
equal effectiveness in preserving or improving ventricular function in established 
DCM [31]. Due to their ability to reduce the fibrotic process and stabilize LV systolic 
function, MRAs should be considered in this phase of DMD-DCM, even in case of 
mild reduction of LVEF, that is much earlier than indicated by current guidelines 
for the management of HF (symptomatic patients with LVEF <35%). In addition, a 
beta blockers (BB) such as carvedilol, is indicated when a sufficient improvement in 
cardiac function is not achieved with the initial therapy with ACE-I/ARB. Routine 
use of the BBs in DMD patients has been controversial in the past years due to con-
flicting results on their efficacy obtained from retrospective and non-randomized 
prospective studies. Nowadays, the superiority of combination therapy with an 
ACE-I/ARB and a BB over monotherapy with ACE-I/ARB is supported by studies 
that have shown more beneficial effect on LV function, on prevention of major car-
diac events (death, deterioration of HF and severe arrhythmias) and on long-term 
survival [32–34]. Furthermore, in DMD-DCM, BBs are also useful to control sinus 
tachycardia caused by autonomic dysfunction and other forms of tachyarrhythmia.
The end-stage DCM is characterized by severe degree of LV dysfunction (LVEF 
<30%) and dilation, the patients might have signs and/or symptoms of HF. Also, 
they may have rhythm disturbances, with a higher risk of acute decompensation of 
HF and sudden cardiac death. Generally this phase occurs after the age of twenty 
Figure 2. 
Cardiac magnetic resonance (CMR), electrocardiographic (EKG) features and clinical status at different 
stages of the DMD-DCM progression. In the pre-clinical stage left ventricular (LV) function is still preserved, 
CMR may identify initial fibrosis, at the EKG some alterations such as QRS fragmentation, rsr’ complexes in 
V1 and alterations of ventricular repolarization may appear, and blood levels of troponin T (TnT) may be 
slightly or moderately high while NTproBNP is normal. The clinical stage is characterized by a certain degree 
of LV dysfunction and dilation, inflammation and fibrotic replacement of the heart muscle are extended, as 
shown by the wide distribution of late gadolinium enhancement (LGE) areas at CMR imagines, abnormal Q 
waves appear at the ECG, and the values of TnT and NTpro BNP are usually very high and moderately high 
respectively. In the end-stage, LV dilation and dysfunction are severe, much of the heart muscle is replaced by 
fibrous tissue, filling pressure increases, and episodes of acute heart failure and ventricular arrhythmias become 
frequent, NTproBNP values are very high while TnT values may not be particularly high due to reduced total 
cardiac muscle mass.
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but in some more aggressive forms of CMD it can manifest earlier. At this stage 
of disease every effort must be aimed to reduce acute events and hospitalizations 
and to improve symptoms and quality of life of these patients. Medical treatment 
includes a combination of an ACE-I/ARB, an MRA and a BB at the maximum toler-
ated or recommended dose, according to European and American Guidelines for the 
management of HF [35, 36]. Based on recent evidence of the efficacy of the heart 
rate reduction strategy in lowering the long term incidence of acute adverse events 
in DMD patients with advanced cardiac involvement, ivabradine should be consid-
ered if LVEF remains below 40% and heart rate above 70 bpm despite maximum 
dose of ACE-I/ARB and BB [37]. Furthermore these patients may also benefit from 
treatment with Sacubitril/Valsartan, the first-in-class angiotensin receptor nepri-
lysin inhibitor (ARNI) that in last decade has become part of standard therapy for 
adult HF and it has shown excellent preliminary results in pediatric patients in the 
ongoing PANORAMA-HF trial (DMD patients included).
In end-stage CMD signs and symptoms of systemic or pulmonary congestion 
may be clinically evident and loop diuretics are indicated. For chronic use furo-
semide 1 to 6 mg/kg/die is generally effective, but in some cases the addiction of 
Metolazone, a thiazide-like diuretic, is required. It is important to underline that 
there is no evidence of the effectiveness of loop diuretics in improving survival, so 
they are to be considered only for relieving symptoms [38].
In patients with severe LV dysfunction an antithrombotic therapy should be 
considered in the primary prevention of thromboembolic events, although not 
routinely recommended [39].
As mentioned above, DMD patients are at risk of arrhythmias such as atrial 
fibrillation, atrial flutter and ventricular tachycardia and this risk increases as 
cardiomyopathy progresses. To date, the management of arrhythmias, with drugs 
and devices, in DMD-DCM is based on general international guidelines, as there 
are no specific recommendations for DMD. Implantable cardioverter defibrillator 
(ICD) has gained acceptance in selected patients [40]. The effectiveness of cardiac 
resynchronization therapy (CRT) in these patients seems to be poor probably due to 
the presence of the extensive postero-lateral fibrosis and poorly explored.
Patients with DMD are generally not considered suitable for cardiac transplant 
candidacy due to early walking impairment, predisposition to respiratory complica-
tions, and their short life expectancy. Heart transplant (HTx) has been considered 
in few highly selected cases in which respiratory compromise was not relevant and 
reported [40]. In BMD, HTx is considered in end stage phase of CMP.
Few cases of patients with end-stage DMD-DCM and preserved or only mild 
reduced respiratory function, left ventricle assist device (LVAD) has been consid-
ered as a destination therapy [41, 42]. To date, the international literature about 
LVAD in DMD patients is poor and proper selection of patient and ethical aspect 
should be accurately evaluated case by case. Share decision making process is also 
crucial and exploratory dialog with patients and caregivers should be routinely 
carried out during follow up, not only in urgent situation [43].
Recently, a retrospective study on DMD patients evaluated the effects of 
advanced cardiac therapies (i.e. ICD, LVAD, HTx) on large DMD population. Out of 
436 DMD patients, 9 had ICD placed, 4 had LVAD and 1 HTx. The authors con-
cluded that advanced HF therapies may be used effectively in select subjects with 
DMD but further studies are needed to stratify the risk and select patients [40].
In the process of choosing about advanced cardiac therapies for end-stage 
DMD-DCM an in-depth personalized assessment is crucial, and involves the 
collaboration of the patient and his family with a team of experts composed of 
cardiologists, cardiac surgeons, neuromuscular specialists, anesthetists, pneumolo-
gists, bioethics experts and psychologists.
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6. DMD-specific drugs: corticosteroids and new target therapies
Given their effectiveness in slowing the progression of muscle damage and 
in prolonging the ability to walk and the life-expectancy, corticosteroids such as 
prednisone and deflazacort have become the standard basic treatment of patients 
with DMD from the moment of diagnosis or, in any case, by the age of five [44]. 
While some preclinical studies have suggested that corticosteroids can accelerate 
cardiomyopathy, subsequent clinical studies have supported their beneficial role 
in preserving ventricular function and delaying the progression of heart disease, 
especially by slowing down the inflammation and the fibrotic process and by 
increasing myogenic repair and myoblast proliferation [45].
Schram et al. [46] showed that steroid therapy was associated with a signifi-
cantly lower all-cause mortality rate, due to a substantial reduction in HF–related 
deaths. In this observational study, patients treated with combination of steroid 
and ACE-I, experienced a much lower incidence of new-onset cardiomyopathy than 
those treated without steroid.
In recent years a new MRA, called Vamorolone, has been discovered. This new 
MRA is able to mimic the anti-inflammatory effects of glucocorticoids and it could 
represent, in the near future, an alternative to the others. It has been reported it 
seems to have less side effects and greater antifibrotic effect thanks to the inhibition 
of the aldosterone pathway [47].
Moreover, several other new therapeutic strategies are under investigation, 
focused to mitigate inflammation and fibrosis or to restore the dystrophin expression. 
These last strategy includes:
• the read-through therapies, such as Ataluren (Translarna™, PTC Therap), the 
first molecule approved in Europe for DMD, that enables the transcription of 
mRNA containing premature stop codons;
• the antisense oligonucleotides (AONs) that can bind pre-mRNA in specific 
splicing sites allowing to skip the exons containing mutations and restoring the 
reading frame of the dystrophin;
• the viral gene therapies, that exploit viral vectors to transfer truncated versions 
of dystrophin gene into myocytes;
• the upregulation of Utrophin, a protein similar to dystrophin, that can supply its 
structural function;
• the cell based therapies that consist on the administration of healthy myocytes 
precursors that can colonize skeletal and cardiac muscle of the recipient.
Most of these gene-targeted therapies are still under study and the evaluation 
of their efficacy is mainly based on the increased expression of dystrophin in 
skeletal myocytes and on the slowing of the myopathy progression. Whether these 
therapies are able to increase dystrophin expression equally in skeletal muscle cells 
and in cardiomyocytes is still unclear since the heart cannot be routinely biopsied. 
This is a crucial point as isolated improvement in muscle function would lead to 
increased demand on a weak heart, accelerating the progression of cardiomyopathy. 
In particular, Ataluren has shown a modest increase in dystrophin expression in 
mouse heart, while in a small cohort of humans neither measurable improvement 
nor deterioration in heart function were observed during 24 months of treatment. 
Instead, there are strong evidences regarding the benefit on heart function from 
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gene therapies that use micro-dystrophin genes. In preclinical studies a robust 
expression of micro-dystrophin in cardiomyocytes has been proved, but the high 
dose required may be burdened significant side effects and the presence of micro-
dystrophin instead of wild-type dystrophin can still lead to the development of a 
BMD-like cardiomyopathy. Further studies are needed to better understand the 
long-term effects of these therapies on the heart [48].
6.1 Cardiomyopathy in DMD female carriers
Most women carrying the DMD mutation in one of the two X chromosomes are 
asymptomatic for life due to the presence of sufficient normal dystrophin produced 
by the unchanged allele of the gene. Some of these women, called “manifesting 
carriers”, may have mild or moderate forms of myopathy and cardiomyopathy; 
this is probably due to a mosaic inactivation of the healthy allele in skeletal and 
heart muscles, or simply to the reduced total amount of normal dystrophin in the 
cells. In particular, cardiomyopathy can occur in up to 8% of cases and symptoms 
can appear from adolescence to late adulthood even without any correlation with 
musculoskeletal manifestations [49]. Therefore, current guidelines recommend to 
perform echocardiography every 5 years in all adult dystrophinopathy carriers [14]. 
The severity of disease can vary widely and can worsen during concomitant events 
such as pregnancy and childbirth. It is interesting to note that in 45% of DMD carri-
ers, subepicardial LGE in the inferolateral free LV wall is detectable at CMR as well 
as in the initial forms of cardiomyopathy in DMD male patients and this is associ-
ated with myocardial enzyme release and with a greater probability of progression 
of the cardiomyopathy [50].
7. Conclusion
Given the primary role of cardiomyopathy in determining the prognosis 
of DMD patients, every effort should be focused on preventing or slowing the 
progression of their cardiac dysfunction. Many drugs commonly used for HF have 
proven to be quite effective, especially if used from the very early stages of the 
disease, before heart dysfunction becomes evident. So current recommendations 
underline the importance of routinely cardiac evaluation since the diagnosis of 
DMD to early recognize heart abnormalities and start ACE-I. In this preclinical 
stage of DMD-DCM, CMR plays a substantial role due to its sensitivity in iden-
tifying initial areas of fibrotic replacement of the heart muscle. Because of the 
lack of specific DMD-DCM therapies, current drugs used for HF might be used 
and further studies are required to address their efficacy, especially at end-stage 
DCM. To date some new target therapies are available and many others are under 
evaluation, so that in the near future we will be able to count on a much wider 
range of specific therapeutic possibilities than now. Moreover, in the end-of- life 
management, ethical issues are still a matter of intense debate in order to identify 
potential advanced cardiac therapies candidates. Surely, in this challenging course 
of treatment, sharing decisions with the patient and his caregivers and the support 
of a multidisciplinary team are crucial cornerstones for obtaining the best possible 
results.
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